| NCT ID | NCT03647098 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hunan Province Tumor Hospital |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2018-08-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2018-08-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.
Eligibility Criteria
Inclusion Criteria: 1. Understand the requirements and contents of the clinical trial . 2. Age ≥ 18 years. 3. Histopathology or cytology confirmed lung cancer 4. ECOG \<=2. 5. Predicted survival ≥ 12 weeks. 6. Adequate bone marrow hematopoiesis and organ function 7. Presence of measurable lesions according to RECIST 1.1. Exclusion Criteria: 1. Subjects who have received any of the following treatments must be excluded: * Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose. * Ongoing (or inability to discontinue) possibly potent CYP1A2, CYP3A inhibitor (1 week), or inducer (2 weeks) drug therapy or herbal supplements within 1-2 weeks prior to the first dose. 2. Presence of spinal cord compression or meningeal metastasis. 3. History of other malignant tumors within 2 years. 4. Adverse events (except alopecia of any degree) of CTCAE \> grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose. 5. History of stroke or intracranial hemorrhage within 6 months prior to the first dose. 6. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator. 7. Subjects with persistent or active infection, including but not limited to hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) and COVID-19 infection. 8. Heart-related diseases or abnormalities 9. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy. 10. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb drugs due to previous bowel resection. 11. Live vaccine was given 2 weeks before the first medication. 12. Women who are breastfeeding or pregnant. 13. Hypersensitivity to the test drug and the ingredients. 14. Other conditions assessed by the investigator to be unsuitable for participation in the study.
Contact & Investigator
Yongchang Zhang, MD
PRINCIPAL INVESTIGATOR
zhangyongchang@csu.edu.cn
Frequently Asked Questions
Who can join the NCT03647098 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03647098 currently recruiting?
Yes, NCT03647098 is actively recruiting participants. Contact the research team at zhangyongchang@csu.edu.cn for enrollment information.
Where is the NCT03647098 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT03647098 clinical trial?
NCT03647098 is sponsored by Hunan Province Tumor Hospital. The principal investigator is Yongchang Zhang, MD at zhangyongchang@csu.edu.cn. The trial plans to enroll 20,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.